Showing results (681-690 of 977) with videos related to

Sort By:
Pageof 98
NPJ Breast Cancer|March 30, 2024
Automated mitotic spindle hotspot counts are highly associated with clinical outcomes in systemically untreated early-stage triple-negative breast cancerRoberto A Leon-Ferre, Jodi M Carter, David Zahrieh, et al.
NPJ Breast Cancer|January 18, 2024
Alternative dosing regimen of exemestane in a randomized presurgical trial: the role of obesity in biomarker modulationHarriet Johansson, Aliana Guerrieri-Gonzaga, Sara Gandini, et al.
NPJ Breast Cancer|September 5, 2024
BRCA genetic testing and counseling in breast cancer: how do we meet our patients' needs?Peter Dubsky, Christian Jackisch, Seock-Ah Im, et al.
NPJ Breast Cancer|October 8, 2024
Discerning the impact of ctDNA detection on patient decision-making in early-stage breast cancerTarah J Ballinger, Mary Lou Smith, Elda Railey, et al.
NPJ Breast Cancer|August 1, 2024
Estrogen levels in young women with hormone receptor-positive breast cancer on ovarian function suppression therapyMegan E Tesch, Yue Zheng, Shoshana M Rosenberg, et al.
NPJ Breast Cancer|July 30, 2024
GAIN2 trial overall survival with intense versus tailored dose dense chemotherapy in early breast cancerVolker Möbus, Hans-Joachim Lück, Ekkehart Ladda, et al.
NPJ Breast Cancer|September 30, 2024
Computerized cognitive training improves cognitive function in primary breast cancer survivorsKarl R Kleinknecht, Mira Bierend, Lisa-Maria Keim, et al.
NPJ Breast Cancer|May 14, 2025
Effects of pregnancy on breast cancer immunology: immune biomarker and TIL quantificationKristin Galas, Moritz Gleitsmann, Julia Rey, et al.
NPJ Breast Cancer|March 30, 2025
Mapping the current landscape of locoregional therapy de-escalation trials in early breast cancer: a systematic reviewAlan D McCrorie, Hilary Stobart, David Dodwell, et al.
NPJ Breast Cancer|April 15, 2025
Multicenter retrospective cohort study of the sequential use of the antibody-drug conjugates (ADCs) trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in patients with HER2-low metastatic breast cancer (MBC)Laura A Huppert, Reshma Mahtani, Samantha Fisch, et al.
Pageof 98